HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Figure 3

Mean HER2 copies and HER2/CEP17 ratios by post-neoadjuvant treatment residual cancer burden categories.